Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Neil Thapar
AddedMay 6, 2026
UpdatedMay 31, 2026
Neil Thapar

Neil Thapar

Co-Founder, Board Chairman, Chief Executive Officer & Chief Scientific Officer, Barricade Therapeutics· 2017 – present · 9 yrs

LinkedIn

Neil Thapar's Career

Barricade Therapeutics
Barricade Therapeutics

Fort Worth, TX, US

Co-Founder, Board Chairman, Chief Executive Officer & Chief Scientific Officer· C-Level · Executive
2017 – present · 9 yrs

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Neil Thapar's Career

Barricade Therapeutics
Barricade Therapeutics
Angel$17.3M32017Fort Worth, TX, US
Co-Founder, Board Chairman, Chief Executive Officer & Chief Scientific Officer· C-Level · Executive
2017 – present · 9 yrs

Recent news

Barricade Therapeutics Launches StartEngine CampaignBio North Texas · 2026
Barricade Therapeutics BT-1501 Phase 1 Trial Targeted for H2 2026KingsCrowd · 2026
TMCi's Accelerator for Cancer Therapeutics is Launching the Future of Oncology InnovationTexas Medical Center · 2025

Leadership at Barricade Therapeutics

Carlos GuillemCarlos GuillemBoard Director
Darlene BoudreauxDarlene BoudreauxBoard Director
Scott JordanScott JordanChief Financial Officer
Mariam MorrisMariam MorrisChief Operating Officer
John WallingJohn WallingCo-Founder, SVP Chemistry, Manufacturing & Controls

Similar to Barricade Therapeutics

Guardian TherapeuticsGuardian TherapeuticsLexington, MA, USTherapeuticsest. 2017Guardian TherapeuticsLexington, MA, US · est. 2017

Guardian Therapeutics, pioneering the limitless potential of aptamer therapeutics.

Series B · $30M75
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Starton TherapeuticsStarton TherapeuticsParamus, NJ, USCancer Therapiesest. 2017Starton TherapeuticsParamus, NJ, US · est. 2017

Starton Therapeutics: A clinical-stage biotech firm innovating cancer care with transdermal technology.

Pre-Seed · $8.5M38

Neil Thapar's Similar Executives & Operators

Ma HuatengMa HuatengChairman · TencentBrian NiccolBrian NiccolChairman and Chief Executive Officer · StarbucksNuno SebastiaoNuno SebastiaoCo-Founder, Chairman, and CEO · FeedzaiDavid LarsonDavid LarsonChief Financial Officer · FeedzaiEtai HochmanEtai HochmanCo-Founder & CTO · At-BayRotem IramRotem IramCo-Founder & CEO · At-BayRoman ItskovichRoman ItskovichCo-Founder & Chief Risk Officer · At-BayTim ZhengTim ZhengChairman · Apollo.io

People Similar to Neil Thapar

Thariq ShihiparThariq ShihiparCo-Founder · MultiverseNeil KelleherNeil KelleherBoard Member and Co-Founder · ImmProNeal LathiaNeal LathiaCo-founder & CTO · Gradient LabsSrinath SridharSrinath SridharCo-Founder & CEO · RegieNeel SharmaNeel SharmaFounder · SentrialNisarg PatelNisarg PatelCo-Founder · Million